Establishing Impurity Acceptance Criteria as Part of Specs for DMFs Based on Clinical Relevance

Submit proposed questions on this poster to [email protected] by March 19, 2021, and tune in for the subsequent panel discussion during the Drug Master File (DMF) and Drug Substance follow-up webinar on April 9, 2021.
To review posters and register for the webinar, visit: https://www.fda.gov/drugs/news-events...

This poster discusses considerations on establishing impurity limits in various cases.

To view all posters and conference presentations, visit: https://www.fda.gov/drugs/news-events...
To listen to a Q&A on poster and conference topics, visit: https://www.fda.gov/drugs/news-events...

FDA CDER’s Small Business and Industry Assistance (SBIA) educates and provides assistance in understanding the regulatory aspects of human drug products & clinical research.    

Upcoming Training - https://www.fda.gov/cdersbia
SBIA Listserv - https://public.govdelivery.com/accoun...
SBIA 2021 Playlist -    • 2021 CDER Small Business and Industry...  
SBIA LinkedIn:   / cder-small-business-and-industry-assistance  
SBIA Training Resources - https://www.fda.gov/cdersbialearn
Twitter -   / fda_drug_info  
Email - [email protected]  
Phone - (301) 796-6707 I (866) 405-5367